Clinical trial NCT05950841: Safety and Effectiveness of IHAT in Iron Deficient Pre-menopausal Woman
Official title: A Randomised, Double-blind Study to Determine the Safety and Efficacy of IHAT in Iron Deficient Premenopausal Women.
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE3
Conditions: Iron-deficiency
Lead sponsor: RDC Clinical Pty Ltd
Sponsor class: INDUSTRY
Collaborators: name: Nemysis Ltd
First posted: 2023-07-18
Enrollment: 180
Sex: FEMALE
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: This is a double blind, randomised, placebo-controlled trial to evaluate orally-dosed IHAT (iron hydroxide adipate tartrate) at 2 different doses compared to placebo for increasing serum ferritin levels in iron-deficient but otherwise healthy premenopausal women over 12 weeks.


Eligibility criteria: Inclusion Criteria:

* Generally healthy iron deficient pre-menopausal women
* Iron deficiency defined as Serum ferritin \< 30 ug/L (1)
* Generally healthy defined as C-reactive protein \< 3 mg/L (1)
* Subjects adhering to a vegetarian or vegan diet are allowed
* Agree not to give blood donations during the study
* Able to provide informed consent
* Agree not to participate in another clinical trial while enrolled in this trial
* Agree not to change current diet and/or exercise frequency or intensity

Exclusion Criteria:

* Anaemia (as determined from the haematocrit and haemoglobin measures) (2)
* Previously told they have an iron absorption problem
* Subjects regularly taking iron specific supplements during or 2 months prior to study commencement (the use of other mineral/vitamin/herbal preparations is allowed but should be recorded) (3)
* Any uncontrolled serious illness (4)
* Receiving/prescribed coumadin (Warfarin), heparin, dalteparin, enoxaparin or other anticoagulation therapy
* Active smokers, nicotine use, alcohol(5) or drug (prescription or illegal substances) abuse
* Chronic gastrointestinal disorders
* Pregnant/lactating women or women trying to conceive
* Diagnosed depression or mental disorder that is uncontrolled
* Eating disorders
* BMI \> 35 kg/m2
* Allergic to any of the ingredients in active or placebo formula
* Any condition which in the opinion of the investigator makes the participant unsuitable for inclusion
* Participants who have participated in any other clinical trial during the past 1 month

Footnotes

1. A blood test is required prior to enrolment into the study to receive trial product. Participants will be required to attend a local pathology collection centre and have serum ferritin and CRP within the required limits to be considered enrolled in the study and be provided with trial product.
2. Anyone considered to be anaemic will be excluded and directed to their GP. In women, anaemia is defined as any of the following: Haemoglobin \< 115 g/L, Haematocrit \< 35%.
3. Potential participants that are taking supplements that would result in their exclusion must wait an 8-week washout period prior to commencing the study.
4. An uncontrolled illness is any illness that is currently not being treated with a stable dose of medication or is fluctuating in severity. A serious illness is a condition that carries a risk of mortality, negatively impacts quality of life and daily function and/or is burdensome in symptoms and/or treatments.
5. Chronic past and/or current alcohol use (\>14 alcohol drinks/week).

Primary outcomes:
measure: Percentage of women recovering from ID at week 12
timeFrame: Week 12
Secondary outcomes:
measure: Time to reach normalisation of ferritin levels
timeFrame: Baseline, week 6 and week 12
measure: Iron Status
timeFrame: Baseline, week 6 and week 12
measure: Incidence and prevalence of gastrointestinal side effects
timeFrame: Baseline, weeks 1 - 5, week 6 and week 12
measure: Change in fatigue
timeFrame: Baseline, week 6 and week 12
measure: Iron deficiency symptoms
timeFrame: Baseline, week 6 and week 12
Other outcomes:
Locations:
city: New Farm
country: Australia
facility: RDC Clinical Pty Ltd
state: Queensland
Study officials:
affiliation: RDC Clinical Pty Ltd
name: Amanda Rao, PhD
role: PRINCIPAL_INVESTIGATOR
References: